Positive Data on Infinity Pharma Candidate – Zacks.com
|
Positive Data on Infinity Pharma Candidate
Zacks.com The study will evaluate the safety and efficacy of IPI-145 in iNHL patients whose disease is refractory to radioimmunotherapy or to both Roche/Biogen Idec Inc.’s (RHHBY)/(BIIB – Analyst Report) Rituxan (rituximab) and chemotherapy and who have … Infinity Reports Updated Phase 1 Data of IPI-145 in Indolent Non-Hodgkin …Business Wire (press release) Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B …MarketWatch |